Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
9.91
Dollar change
+0.32
Percentage change
3.34
%
IndexRUT P/E- EPS (ttm)-5.65 Insider Own8.72% Shs Outstand96.79M Perf Week-2.65%
Market Cap959.39M Forward P/E- EPS next Y-1.49 Insider Trans0.84% Shs Float88.37M Perf Month-4.80%
Income-311.46M PEG- EPS next Q-0.74 Inst Own100.07% Short Float16.97% Perf Quarter228.15%
Sales3.69M P/S260.00 EPS this Y34.20% Inst Trans9.83% Short Ratio2.83 Perf Half Y77.60%
Book/sh0.92 P/B10.82 EPS next Y40.15% ROA-72.65% Short Interest14.99M Perf Year-3.22%
Cash/sh2.82 P/C3.52 EPS next 5Y9.80% ROE-122.80% 52W Range1.76 - 15.40 Perf YTD206.81%
Dividend Est.- P/FCF- EPS past 5Y-48.07% ROI-105.99% 52W High-35.65% Beta1.14
Dividend TTM- Quick Ratio6.80 Sales past 5Y303.42% Gross Margin54.02% 52W Low463.07% ATR (14)0.87
Dividend Ex-Date- Current Ratio7.08 EPS Y/Y TTM-35.85% Oper. Margin-8183.04% RSI (14)52.96 Volatility7.64% 9.62%
Employees296 Debt/Eq2.32 Sales Y/Y TTM- Profit Margin-8449.76% Recom1.57 Target Price18.00
Option/ShortYes / Yes LT Debt/Eq2.31 EPS Q/Q62.05% Payout- Rel Volume0.70 Prev Close9.59
Sales Surprise18.56% EPS Surprise7.94% Sales Q/Q1765.66% EarningsFeb 27 BMO Avg Volume5.29M Price9.91
SMA20-4.48% SMA5021.68% SMA20054.29% Trades Volume3,723,600 Change3.34%
Date Action Analyst Rating Change Price Target Change
Jan-03-24Upgrade Mizuho Neutral → Buy $4 → $8
Oct-26-23Downgrade Mizuho Buy → Neutral $57 → $4
Oct-13-23Downgrade Goldman Buy → Neutral $32 → $6
Sep-07-22Initiated Needham Buy $46
Mar-17-22Initiated Goldman Buy $45
Jun-30-21Initiated Mizuho Buy $58
May-27-21Upgrade Morgan Stanley Equal-Weight → Overweight $52
Nov-09-20Upgrade Goldman Neutral → Buy $34 → $36
Oct-08-20Initiated Truist Buy $38
Feb-25-20Initiated Guggenheim Buy $36
Today 08:00AM
Mar-19-24 09:55AM
Mar-18-24 09:55AM
Mar-11-24 08:00AM
Mar-10-24 04:00PM
04:00PM Loading…
Mar-09-24 04:00PM
Mar-08-24 07:33PM
Mar-05-24 04:00PM
Mar-04-24 04:00PM
08:00AM
Mar-01-24 09:55AM
09:40AM
Feb-29-24 05:00PM
11:33AM
Feb-28-24 11:30PM
04:10PM Loading…
04:10PM
04:00PM
12:16AM
Feb-27-24 08:11AM
05:50AM
Feb-16-24 08:00AM
Feb-06-24 04:00PM
Feb-01-24 03:04PM
Jan-31-24 08:00AM
Jan-29-24 08:00AM
Jan-22-24 08:00AM
Jan-18-24 12:00PM
Jan-14-24 04:00AM
04:00AM
Dec-23-23 07:32PM
11:48AM Loading…
Dec-19-23 11:48AM
Dec-18-23 06:02AM
04:58AM
Dec-15-23 05:19PM
05:14PM
05:11PM
Dec-01-23 10:00PM
Nov-29-23 08:00AM
Nov-17-23 09:35AM
Nov-16-23 11:04PM
Nov-15-23 01:26PM
Nov-14-23 05:04PM
Nov-05-23 03:55PM
Nov-03-23 09:47AM
07:30AM
Nov-02-23 04:00PM
Nov-01-23 09:35AM
Oct-31-23 09:35AM
Oct-26-23 12:32PM
Oct-25-23 04:00PM
Oct-20-23 08:00AM
Oct-19-23 11:45PM
04:04PM
Oct-13-23 08:00AM
Oct-09-23 08:52AM
Oct-06-23 08:00AM
Oct-05-23 04:00PM
Sep-27-23 08:00AM
04:16AM
Sep-25-23 04:17PM
09:00AM
Sep-19-23 07:30AM
Sep-15-23 04:00PM
Sep-13-23 08:32AM
Sep-12-23 07:30AM
Sep-07-23 03:08PM
08:15AM
Sep-05-23 04:00PM
Aug-31-23 10:12PM
10:33AM
08:00AM
Aug-29-23 08:00AM
Aug-18-23 04:30PM
Aug-13-23 08:08AM
Aug-11-23 06:02AM
Aug-10-23 08:16AM
Aug-09-23 09:23AM
09:11AM
Aug-08-23 06:15PM
04:02PM
Aug-04-23 04:00PM
Jul-24-23 04:00PM
Jul-17-23 08:00AM
Jul-05-23 04:00PM
Jun-09-23 05:33PM
Jun-06-23 04:00PM
Jun-05-23 04:00PM
May-24-23 05:00PM
May-18-23 04:37PM
May-09-23 05:45PM
04:02PM
May-05-23 04:00PM
May-02-23 08:00AM
Apr-28-23 04:01PM
Apr-25-23 04:00PM
Apr-18-23 08:00AM
Apr-12-23 04:45PM
Apr-07-23 04:00PM
Apr-05-23 08:00AM
Mar-18-23 07:00AM
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Heron Patrick JDirectorMar 04 '24Buy9.5021,052199,9948,785,284Mar 06 04:28 PM
Watanabe Todd FranklinSee RemarksMar 04 '24Sale11.1214,903165,739874,533Mar 06 05:09 PM
Burnett PatrickSee RemarksMar 04 '24Sale11.124,78253,182269,300Mar 06 05:12 PM
Matsuda MasaruSee RemarkMar 04 '24Sale11.123,76041,816190,424Mar 06 05:14 PM
Moore Matthew RichardSVP and Chief Business OfficerMar 04 '24Sale11.123,46838,568146,020Mar 06 05:08 PM
Watanabe Todd FranklinSee RemarksFeb 28 '24Sale10.602,46526,129889,436Mar 01 04:11 PM
Burnett PatrickSee RemarksJan 02 '24Sale3.541,3254,69257,032Jan 03 05:30 PM
Watanabe Todd FranklinSee RemarksDec 01 '23Option Exercise1.6859,525100,038513,682Dec 01 08:51 PM
Matsuda MasaruSee RemarkNov 21 '23Sale1.981,8503,66146,634Nov 21 05:47 PM
Frazier Life Sciences VIII, L.10% OwnerOct 24 '23Buy2.5080,000200,0008,764,232Oct 26 04:09 PM
Burnett PatrickSee RemarksAug 21 '23Sale7.041,60511,30258,357Aug 22 12:24 PM
Watanabe Todd FranklinSee RemarksMay 31 '23Buy6.381,4639,334515,145Dec 01 08:51 PM
Matsuda MasaruSee RemarkMay 31 '23Sale7.801,83014,27842,146Jun 02 08:31 PM
Welgus Howard G.DirectorApr 17 '23Option Exercise1.688,50014,285174,325Apr 18 07:00 PM
Welgus Howard G.DirectorApr 17 '23Sale13.978,500118,728165,825Apr 18 07:00 PM
Welgus Howard G.DirectorApr 06 '23Option Exercise1.688,50014,285174,325Apr 10 04:13 PM
Welgus Howard G.DirectorApr 06 '23Sale12.018,500102,085165,825Apr 10 04:13 PM